Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc (PLUR) pioneers transformative biotechnology solutions through its patented 3D cell expansion platform, driving innovations across regenerative medicine, immunotherapy, and sustainable food production. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, strategic partnerships, and technological breakthroughs.
Access essential updates including earnings announcements, regulatory milestones, and progress in key sectors such as cultivated meat production through subsidiary Ever After Foods. Track advancements in off-the-shelf cell therapies for medical applications and manufacturing collaborations through Pluri's CDMO division.
Our curated news collection serves as your primary source for understanding Pluri's multi-industry impact. Discover updates on clinical trial progress, foodtech innovations, and manufacturing expansions while maintaining awareness of market-moving developments. Bookmark this page for streamlined access to press releases and analysis-free corporate announcements directly from verified sources.
DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.
Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.
Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.
Pluri Inc. (PLUR) has strengthened its intellectual property portfolio with two new patents for 3D expansion of immune cells, granted by the USPTO and Israel. The patents specifically cover MAIT (Mucosal-Associated Invariant T) cell expansion technologies in large-scale bioreactors.
The company's placental MAIT cells platform aims to address solid tumor treatment, targeting the immune cell engineering market (projected at $11.7B by 2030) and cancer immunotherapy market ($136B in 2025). These cells offer unique advantages over conventional T cells, including lower alloreactivity and enhanced tumor-targeting capabilities.
Pluri's IP estate now encompasses over 250 patents pending, allowed, and granted. The technology enables commercial-scale production of 'off-the-shelf' immune cell therapies, with applications extending to Tumor Infiltrating Lymphocytes (TILs).
Pluri Inc. (PLUR) has signed an exclusive collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness. The three-year partnership focuses on stockpiling and distributing Pluri's PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS).
The collaboration aims to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals. If successful, the initiative could generate over $100 million in value for both parties. Hemafund will leverage its biobank infrastructure for storage and distribution across Ukraine.
This strategic initiative comes in response to recent security concerns, including a Russian drone strike on the Chernobyl nuclear power plant. The partnership encompasses:
- Secure storage and distribution systems
- Regulatory compliance support
- Clinical advancement opportunities
- Public and private funding initiatives
Ever After Foods (EAF) and Bühler announced a strategic collaboration to develop commercial-scale cultivated meat production systems. The partnership aims to bring to market a production system that enables commercial production at ten-fold lower scale than existing technologies.
The collaboration leverages EAF's proprietary edible packed-bed (EPB™) technology platform, which can reduce production costs by over 90% while achieving superior production efficiency. The system enables natural production of both muscle and fat tissues for beef, chicken, duck, and fish cells, ensuring exceptional replication of conventional meat.
EAF's technology offers enhanced nutritional value and superior flavor, working with select cultivated meat companies and industry leaders to accelerate global deployment. The partnership with Bühler aims to develop tailored solutions for sustainable scaling of cultivated meat production, moving beyond pharma-based technologies toward food-specific production methods.
Pluri Inc. (PLUR) has secured an additional $3.5 million investment from Merchant Adventure Fund, L.P., a major existing shareholder, bringing total recent financings to $10 million. The investment follows a recent $6.5 million private placement with global investor Alejandro Weinstein.
The new investment involves issuing 759,219 common shares at $4.61 per share and warrants to purchase 45,553 shares at $5.568 per share. The closing is expected around February 20, 2025. The recent $6.5 million investment from Weinstein includes an agreement to acquire Kokomodo and potentially enter the cacao market.
The funds will support Pluri's growth strategy as a global leader in cell-based technology, enabling expansion across pharma, foodtech, and agtech industries. The company views this additional investment as a strong vote of confidence in its vision, technology, and execution strategy.
Pluri Inc. (PLUR) has secured a $6.5 million strategic investment from global investor Alejandro Weinstein at $4.61 per share, representing a premium to market. The investment includes common shares, warrants, and pre-funded warrants. Concurrently, Pluri is acquiring a 71% stake in Kokomodo , an AgTech company specializing in cultivated cacao production, for $4.5 million in Pluri common shares.
The transactions aim to strengthen Pluri's position in sustainable food technologies. As part of the deal, Weinstein will join Pluri's Board of Directors. The investment closing is expected around January 31, 2025, while the Kokomodo acquisition is anticipated to complete in Q2 2025. Both transactions require shareholder approval and other regulatory clearances.
The global cacao market, valued at $13.5 billion in 2023, is projected to reach $23.5 billion by 2030 with an 8.2% CAGR.
Pluri Inc. (PLUR) congratulates Mesoblast on receiving FDA approval for the first MSC-based therapy treating steroid-refractory acute graft-versus-host disease (SR-aGVHD). This milestone validates the therapeutic potential of Mesenchymal Stromal Cell (MSC) therapies in regenerative medicine. Pluri's CEO Yaky Yanay emphasized how this approval marks a significant advancement in cellular medicine and demonstrates the potential of regenerative therapies to transform healthcare by addressing root causes rather than just symptoms.
Pluri continues developing its proprietary 3D cell-expansion technology for MSC therapies, including PLacental eXpanded cells for treating conditions like Acute Radiation Syndrome and Knee Osteoarthritis.
Pluri Inc. (Nasdaq: PLUR) has been shortlisted for the CDMO of the Year Award by the Advanced Therapies Awards 2025 for its PluriCDMO™ business division. Launched in January 2024, PluriCDMO™ offers contract development and manufacturing services to life science companies, providing access to their 47,000 square foot GMP facilities and patented bioreactor system for 3D cell expansion.
The nomination comes less than a year after the division's launch, highlighting Pluri's rapid progress in supporting transformative therapies. The company's technology enables mass-scale production through a fully controlled, automated, and validated process, serving a growing number of innovative clients in the cell therapy industry.
Pluri Inc. (Nasdaq: PLUR) is evaluating its readiness for mass production of PLX-R18, a potential treatment for hematopoietic complications of acute radiation syndrome (H-ARS). The assessment comes amid heightened global nuclear threats, particularly in Ukraine. PLX-R18 has shown promise in improving survival and accelerating recovery from H-ARS in preclinical studies, with support from U.S. defense agencies. The treatment has received FDA's Orphan Drug Designation and IND approval for H-ARS treatment. The company's manufacturing facility is equipped for large-scale cellular therapy production and could be mobilized for mass production if needed.
Pluri Inc. (NASDAQ: PLUR), a biotechnology company specializing in cell-based solutions, has announced its participation in the upcoming Q4 Virtual Investor Summit Microcap Event on November 21st. The company will deliver a presentation from 9:00 AM to 9:30 AM ET and will be available for one-on-one meetings throughout the day.
The event showcases 40 micro-cap companies with catalysts and strong market performance. It features live Q&A sessions and is complimentary for qualified investors. The presentation will be accessible via webcast.
